A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition

Phase 4 Completed 24 enrolled Watson Pharmaceuticals

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy and safety of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in adults who have spinal cord injury.

Timeline

Start: 2004-12
Primary completion: 2005-12
Completion: 2008-05

Outcome

Met primary endpoint

paper Daily number of CIC periods without leakage increased significantly (mean change, 1.5 + or - 2.2; P = .0036) PMID 19628264 ↗

Publications

Results Kennelly MJ, Lemack GE, Foote JE, Trop CS. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Urology. 2009 Oct;74(4):741-5. doi: 10.1016/j.urology.2009.05.008. Epub 2009 Jul 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Oxybutynin	Small molecule	3.9 mg	Other
Subject	Oxybutynin	Small molecule	7.8 mg	Other
Subject	Oxybutynin	Small molecule	9.1 mg	Other
Subject	Oxybutynin	Small molecule	11.7 mg	Other